Drug Information

Drug General Information
Drug ID
D0YG4I
Former ID
DCL001069
Drug Name
Bevasiranib
Drug Type
siRNA drug
Indication Exudative age-related macular degeneration [ICD9: 362.5; ICD10:H35.3] Discontinued in Phase 3 [550053]
Therapeutic Class
siRNA
Company
Opko Health
CAS Number
CAS 849758-52-7
Target and Pathway
Target(s) Vascular endothelial growth factor A Target Info Modulator
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
mTOR signaling pathway
PI3K-Akt signaling pathway
VEGF signaling pathway
Focal adhesion
Pathways in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Renal cell carcinoma
Pancreatic cancer
Bladder cancer
Rheumatoid arthritis
NetPath Pathway IL2 Signaling Pathway
EGFR1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
TSH Signaling Pathway
Leptin Signaling Pathway
FSH Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathway
Pathway Interaction Database Glypican 1 network
HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
S1P3 pathway
Signaling events mediated by TCPTP
S1P1 pathway
Alpha9 beta1 integrin signaling events
Integrins in angiogenesis
VEGFR1 specific signals
HIF-1-alpha transcription factor network
Reactome Platelet degranulation
Regulation of gene expression by Hypoxia-inducible Factor
VEGF ligand-receptor interactions
VEGF binds to VEGFR leading to receptor dimerization
WikiPathways SIDS Susceptibility Pathways
Hypertrophy Model
Endochondral Ossification
Focal Adhesion
Differentiation Pathway
Bladder Cancer
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
Nifedipine Activity
Aryl Hydrocarbon Receptor
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
Integrated Pancreatic Cancer Pathway
Oncostatin M Signaling Pathway
Allograft Rejection
Integrated Breast Cancer Pathway
Signaling by VEGF
Heart Development
Angiogenesis
References
Ref 5500532011 Pipeline of Acuity Pharmaceuticals.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.